


LDN 193688

Chemical Properties

CAS No. : 1062368-51-7
 Formula: C₂₂H₁₆N₄O
 Molecular Weight: 352.39
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

| | |
|---------------|---|
| Description | LDN 193688 is a BMP kinase inhibitor preferential for the ALK2 site, acting by binding to the ALK site, with BMP inhibitory activity 100 times that of TGFβRI, used in the study of progressive osseous fibrodysplasia. |
| Targets(IC50) | ALK,TGF-beta/Smad |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.8378 mL | 14.1888 mL | 28.3776 mL |
| 5 mM | 0.5676 mL | 2.8378 mL | 5.6755 mL |
| 10 mM | 0.2838 mL | 1.4189 mL | 2.8378 mL |
| 50 mM | 0.0568 mL | 0.2838 mL | 0.5676 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Engers DW, et, al. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1,5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.

Cuny GD, et, al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4388-92.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481